THE CORPORATE REPUTATION OF THE PHARMA INDUSTRY IN 2015: THE PERSPECTIVE OF 111 PATIENT GROUPS  with an interest in HEPATITIS (1st edition)

Report published by PatientView

24th August 2016

 

COMPANIES ASSESSED FOR ...

  1. Patient centricity.
  2. Provision of patient information.
  3. Patient safety.
  4. Usefulness of products.
  5. Record of transparency.
  6. Integrity.

THE 14 COMPANIES ASSESSED ...

AbbVie I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Gilead  Sciences I GSK I Janssen I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I ViiV Healthcare
 
 

If you would like more information, or would like to get hold of this report, please use contact details below.

Contact: Alex Wyke     Email: report@patient-view.com   Website: http://www.patient-view.com

 

About this report

London, Wednesday 24th August 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 111 patient groups with an interest in hepatitis. The report provides feedback (from the perspective of  these patient groups) on the corporate reputation of the pharma industry during 2015, as well as on the performance of  14 pharma companies at six key indicators that influence corporate reputation. The 2015 results are compared with those from patient groups across all therapy areas in the 2015 survey.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

 

WHAT THE PATIENT GROUPS SAID ...

“I think that scenarios such as the exorbitant cost of hepatitis-C drugs have perpetuated the notion of industry only caring about shareholders and profits above patient satisfaction, or even caring to offer access to life-saving medications.”

—Regional Canada-based patient group specialising in hepatitis, HIV/AIDS, and sexual health

 

“Pricing at what you can get out of the system, rather than a fair price, leaves many people unable to access needed medications. ”

—National Scotland-based patient group specialising in hepatitis and HIV/AIDS

 

INDUSTRY-WIDE FINDINGS

The 111 patient groups with an interest in hepatitis and responding to the 2015 ‘Corporate Reputation of Pharma’ survey were more positive about the pharma industry’s corporate reputation than the equivalent average from patient groups across all therapy areas in 2015.

 

47.6% of the 111 patient groups with an interest in hepatitis and responding to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. The equivalent figure for patient groups from across all therapy areas in 2015 was slightly lower, at 44.7%.

Patient groups with an interest in hepatitis ranked the pharma industry 5th out of 8 healthcare-industry sectors for corporate reputation in 2015—ahead of generics, for-profit, and not-for-profit health insurers. Pharma also ranked 5th in 2015’s global results.

 

In 2015, hepatitis patient groups were more impressed than patient groups from any other disease area by pharma’s ability to be innovative, and to provide high-quality products.

  • As many as 74% of the patient groups with an interest in hepatitis responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at being innovative—a higher figure than any reported by patient groups from other therapeutic areas. The equivalent figure from patient groups across all therapy areas in 2015 was 69%.

  • 81% of the patient groups with an interest in hepatitis responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at providing high-quality products—again, a higher figure than from patient groups of any other therapy area. The equivalent figure from patient groups across all therapy areas 2015 was noticeably lower, at 72%. wide in 2015 was 15%.

 

BUT ...

Patient groups with an interest in hepatitis marked the industry down in 2015 for the following:

  • Only 7% of patient groups with an interest in hepatitis thought pharma “Excellent” or “Good” at having fair pricing policies in 2015—a lower figure than reported by patient groups from other therapeutic areas. The equivalent figure among patient groups across all therapy areas in 2015 was 15%.
  • Only 19% of patient groups with an interest in hepatitis thought pharma “Excellent” or “Good” at being transparent in 2015—again, a lower figure than reported by patient groups from other therapeutic areas. The equivalent figure among patient groups across all therapy areas in 2015 was 26%.

The most-important single strategy that a pharma company can embrace to improve its corporate reputation, according to 42% of the 111 patient groups with an interest in hepatitis, is: having a fair pricing policy. The percentage is higher than from patient groups of any other therapy area (21% of patient groups from across all therapy areas in 2015 stated the same about fair pricing). Many patient groups regard pricing as among the most contentious of subjects in 2015. They firmly believe that high prices can deny patients access to important treatments.

 

HOW INDIVIDUAL PHARMA COMPANIES PERFORMED FOR CORPORATE REPUTATION AMONG PATIENT GROUPS WITH AN INTEREST IN HEPATITIS IN 2015

 

Patient groups with an interest in hepatitis ranked Janssen overall 1st out of 14 pharma companies for corporate reputation in 2015. They ranked Gilead Sciences 1st for the corporate-reputation indicator of high-quality products. The highest-ranking companies typically supply treatments; the lowest ranking supply vaccines.

ABOUT THE RESPONDENTS:

Many of 2015’s respondent 111 patient groups with an interest in hepatitis were dedicated to the disease. However, the 111 also included some sexual-health umbrella patient groups, a number of patient groups associated with HIV/AIDS, as well as with hepatitis, and some patient groups specialising in public health. The 111 came from 30 countries.

 

 

WHY VIIV HEALTHCARE IS INCLUDED IN THE RANKINGS 

Companies analysed in this report supply hepatitis treatments, and/or vaccines, and/or diagnostics. 43 of the 111 patient groups with an interest in hepatitis stated that they were familiar with ViiV Healthcare. All 43 patient groups specialised in both hepatitis and HIV/AIDS. ViiV’s primary focus is on HIV/AIDS medicines. The responses from these 43 patient groups reflect the views of patients who have both hepatitis and HIV/AIDS.

 
CLICK HERE: FOR CONTENTS AND TABLES
 

END OF STATEMENT

PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.

 
www.patient-view.com